Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a study titled ‘Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA).’ The study aims to assess the effectiveness of combining ixekizumab and tirzepatide in improving psoriatic arthritis symptoms and achieving weight reduction in adults with obesity or overweight.
The interventions being tested are ixekizumab and tirzepatide, both administered subcutaneously. Ixekizumab is used for treating psoriatic arthritis, while tirzepatide is intended to aid in weight reduction.
This interventional study is designed as a randomized, parallel assignment with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either ixekizumab alone or in combination with tirzepatide.
The study began on September 24, 2024, with an estimated completion timeline not yet disclosed. The latest update was submitted on July 1, 2025, indicating the study is active but not recruiting participants.
This study could impact Eli Lilly’s stock performance by potentially expanding its market share in treating psoriatic arthritis and obesity. Positive results might enhance investor confidence, especially given the competitive landscape in the pharmaceutical industry.
The study is ongoing, with further details available on the ClinicalTrials portal.